All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory AML treatment with venetoclax and hypomethylating agents (HMAs)?
What is the real-world experience of R/R AML treatment with venetoclax + HMAs?
In this video, DiNardo explains how the response rate of this regimen compares to other salvage chemotherapy options. She highlights that patients in the relapse setting have a higher chance of responding to this HMA regimen, including patients with diploid cytogenetics or MPN1, IDH1, and IDH2 mutations.
1st NCRI AML academy meeting | What is the optimum treatment strategy for elderly or frail patients with AML?
Prof Courtney DiNardo spoke to us at the 1st NCRI AML academy meeting on the topic of the optimum strategy for the treatment of elderly or...
Venetoclax in combination with hypomethylating agents for the treatment of older patients with NPM1-mutated acute myeloid leukemia
Approximately 30% of patients with acute myeloid leukemia (AML) have nucleophosmin-1 mutations (NPM1+), which are...
Subscribe to get the best content related to AML delivered to your inbox